Company news
Ernexa Therapeutics Inc. (NASDAQ:ERNA) news
Every Ernexa Therapeutics Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
August 27, 2026
Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies
July 24, 2026
Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Stud...
July 14, 2026
Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients
June 25, 2026
Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission a...
June 17, 2026
Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual...
June 9, 2026
Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical D...
May 27, 2026
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ER...
May 20, 2026
Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian C...
May 6, 2026
Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split
April 30, 2026
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
February 20, 2026
Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering
February 6, 2026
Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA
February 3, 2026
Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program
January 27, 2026
Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer
January 6, 2026
Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate f...
December 8, 2025
Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting
December 3, 2025
Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D...
December 2, 2025
Ernexa Therapeutics to Present at Oxford Global’s Cell 2025
November 11, 2025
Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Ther...
November 10, 2025
Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investo...
November 6, 2025
/C O R R E C T I O N -- Cellipont Bioservices/
October 29, 2025
Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa
October 1, 2025
Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit
September 29, 2025
Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research
September 17, 2025
Ernexa Therapeutics Provides Update on Operational Excellence and Performance
September 10, 2025
Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference
September 3, 2025
Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements
July 9, 2025
Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development
June 25, 2025
Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement
June 24, 2025
Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split
June 10, 2025
Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025
May 28, 2025
Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations
May 14, 2025
Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference
May 8, 2025
Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025
April 29, 2025
Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025
April 22, 2025
Ernexa Therapeutics Closes New Funding Round
April 3, 2025
Eterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Cancer and Autoimmune Disease
March 25, 2025
Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline
February 26, 2025
Eterna Therapeutics Announces Expansion of Scientific Advisory Board
January 28, 2025
Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer
January 14, 2025
Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors
January 9, 2025
Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate’s (ERNA-101) Ability to Induce...
December 3, 2024
Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program
November 25, 2024
Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Suc...
October 30, 2024
Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development f...
October 17, 2024
Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board
May 8, 2024
Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors
February 20, 2024
Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)
January 3, 2024
Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer
December 20, 2023